Brokers Offer Predictions for ACHV Q3 Earnings

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – Investment analysts at Zacks Small Cap issued their Q3 2025 earnings per share estimates for shares of Achieve Life Sciences in a research report issued on Wednesday, May 14th. Zacks Small Cap analyst J. Vandermosten expects that the biopharmaceutical company will earn ($0.22) per share for the quarter. The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.17) per share. Zacks Small Cap also issued estimates for Achieve Life Sciences’ Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($1.11) EPS, FY2026 earnings at ($1.07) EPS and FY2027 earnings at $0.69 EPS.

Achieve Life Sciences (NASDAQ:ACHV) last posted its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.37).

Achieve Life Sciences Price Performance

ACHV opened at $3.08 on Friday. The stock’s 50-day moving average price is $2.48 and its 200 day moving average price is $3.30. Achieve Life Sciences has a 12-month low of $1.84 and a 12-month high of $5.59. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.31. The firm has a market cap of $106.83 million, a price-to-earnings ratio of -2.73 and a beta of 1.49.

Institutional Investors Weigh In On Achieve Life Sciences

A number of hedge funds have recently bought and sold shares of ACHV. Barclays PLC raised its position in Achieve Life Sciences by 303.1% in the 3rd quarter. Barclays PLC now owns 47,655 shares of the biopharmaceutical company’s stock valued at $226,000 after purchasing an additional 35,832 shares in the last quarter. SG Americas Securities LLC raised its position in Achieve Life Sciences by 74.8% in the 4th quarter. SG Americas Securities LLC now owns 19,886 shares of the biopharmaceutical company’s stock valued at $70,000 after purchasing an additional 8,512 shares in the last quarter. Sigma Planning Corp acquired a new stake in Achieve Life Sciences in the 4th quarter valued at about $37,000. SBI Securities Co. Ltd. acquired a new stake in Achieve Life Sciences in the 4th quarter valued at about $49,000. Finally, Raymond James Financial Inc. acquired a new stake in Achieve Life Sciences in the 4th quarter valued at about $554,000. Institutional investors and hedge funds own 33.52% of the company’s stock.

Insider Buying and Selling

In related news, CFO Mark K. Oki purchased 10,000 shares of Achieve Life Sciences stock in a transaction on Monday, March 17th. The shares were bought at an average price of $2.89 per share, with a total value of $28,900.00. Following the transaction, the chief financial officer now directly owns 10,000 shares of the company’s stock, valued at approximately $28,900. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.00% of the stock is owned by corporate insiders.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.